Switching From or To Tresiba (Insulin Degludec): Evidence-Based Protocols

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin analog approved by the FDA for type 1 and type 2 diabetes in adults and children. It is available as U-100 and U-200 FlexTouch pen formulations and is distinct from insulin glargine (Lantus, Basaglar, Toujeo) and insulin detemir (Levemir), which use different molecular mechanisms to extend their duration of action. This article addresses how clinicians and patients commonly manage a switch onto or off of degludec, it does not replace individualized dosing instructions from a prescriber.

Direct answer: For most patients moving from a once-daily basal insulin (glargine U-100, glargine U-300, or detemir once daily) to Tresiba, a 1:1 unit conversion is the standard starting approach described in the FDA-approved prescribing information; no dose change is required for that specific transition. The more consequential decision is not the conversion ratio but the waiting period, degludec accumulates toward steady state over roughly 3 to 4 days because of its long half-life, so titrating before that window closes is a common and avoidable error. When consolidating a twice-daily basal regimen into once-daily degludec, guidance generally supports a dose reduction rather than a straight unit-for-unit sum, because twice-daily regimens carry overlapping insulin action that a single long, flat-acting dose does not replicate.

Why the pharmacokinetics matter for switching, not just the label

Insulin degludec forms soluble multi-hexamer chains at the injection site that slowly release insulin monomers into circulation. This differs from glargine, which precipitates as microcrystals at tissue pH, and from detemir, which binds albumin. The practical consequence for switching is timing, not dosing philosophy: because degludec's action builds gradually over several days, the glucose-lowering effect of a newly started or newly adjusted dose cannot be fully judged until roughly 72 hours have passed. Adjusting the dose before that point risks over- or under-correcting based on an incomplete picture.

The DEVOTE cardiovascular outcomes trial in type 2 diabetes compared degludec with glargine U-100 and reported non-inferiority for major adverse cardiovascular events along with a lower rate of severe nocturnal hypoglycemia in the degludec arm. The magnitude of that hypoglycemia difference is often cited in secondary sources; the precise effect size should be confirmed against the original 2017 New England Journal of Medicine publication before being used in patient-facing materials, since this draft could not independently verify a specific citation link for it.

Switching from glargine U-100 (Lantus, Basaglar) to Tresiba

This is generally described as the most straightforward basal-to-basal transition. The FDA label and standard clinical practice describe a direct 1:1 unit-for-unit conversion with no dose adjustment at the time of the switch.

A reasonable practical sequence:

1. Stop glargine at the usual injection time.
2. Give the same number of units of degludec at the next scheduled basal dose.
3. Check fasting glucose daily, but do not adjust the dose for the first 3 to 4 days.
4. After day 4, titrate in small increments (commonly 2 to 4 units every few days) toward the individualized fasting glucose target set by the prescriber.

Trial data pooling degludec-versus-glargine studies has generally shown comparable A1C outcomes with a lower rate of confirmed hypoglycemia in the degludec arm, though the exact numbers vary by study population and should be checked against the specific trial being cited rather than assumed to generalize.

One practical nuance worth mentioning to patients: those who took morning glargine may notice slightly lower fasting glucose in the first few days after switching to degludec at the same clock time. This likely reflects degludec's flatter profile removing a "waning" effect sometimes seen toward the end of glargine's action window, but this is a plausible mechanistic explanation rather than a formally established finding.

Switching from glargine U-300 (Toujeo) to Tresiba

This conversion needs more individualized judgment than the U-100 switch. Glargine U-300 has a longer duration than U-100 but is typically dosed higher than U-100 to reach equivalent control, a pattern described in the EDITION trial program. Because degludec's potency per unit differs from U-300's, a straight 1:1 switch by total daily dose is the usual starting point, but clinicians should expect to watch closely for hypoglycemia in the first one to two weeks rather than assume the conversion is dose-neutral.

A head-to-head trial (CONCLUDE) compared degludec with glargine U-300 in type 2 diabetes using treat-to-target titration rather than a fixed-dose switch design, so it does not directly validate a specific switch ratio, it supports comparable long-term control between the two ultra-long-acting analogs when each is individually titrated, not a specific conversion formula.

Consolidating twice-daily basal insulin into once-daily Tresiba

Patients on twice-daily NPH, twice-daily detemir, or split-dose glargine represent a different problem: the two doses must be combined into one, and the combined total daily dose typically overstates the true basal requirement once the overlap between doses is removed.

Diabetes care guidelines commonly describe a dose reduction (often in the range of 20%, though the exact percentage should be confirmed against the current guideline text rather than treated as fixed) when consolidating twice-daily basal insulin into once-daily degludec. The rationale is that twice-daily regimens create overlapping insulin action, the second dose supplements the tail of the first, and degludec's flat, non-overlapping profile means the true basal need is lower than the simple sum suggests.

Clinician-and-patient monitoring framework for a Tresiba switch

This is a discussion and monitoring structure, not a substitute for an individualized prescription. It is meant to organize the conversation between a patient and their prescriber during a switch, and to flag when the situation has moved outside routine management.

Before the switch, questions to confirm with the prescriber

• What is my new starting dose, and is it a straight unit conversion or a reduced dose?
• Why is this specific ratio being used for my situation (source insulin, twice-daily vs. once-daily, renal function, prior hypoglycemia history)?
• What is my individualized fasting glucose target, and how does it differ from a generic target?
• Is any mealtime insulin dose expected to change, and if so, when should I expect it?

Days 1 to 3 after the switch, hold period

• Take the new dose at a consistent time; do not adjust it regardless of the fasting readings.
• Check fasting glucose daily and keep a written or app-based log.
• Escalation trigger: any reading below 70 mg/dL, or symptoms of hypoglycemia (shakiness, sweating, confusion) at any point, treat the low per usual hypoglycemia protocol and contact the prescriber before the next dose rather than waiting for day 4.

Day 4 onward, titration window opens

• Review the 3-day fasting glucose average with the prescriber before making any change.
• Typical adjustment increments are small (commonly a few units at a time), spaced several days apart, following the prescriber's specific plan rather than a generic schedule.
• Escalation trigger: fasting glucose consistently and significantly above the individualized target despite the switch, or any single reading suggesting severe hyperglycemia (very high readings, especially with nausea, vomiting, or breathing changes), this warrants same-day contact with the care team rather than waiting for the next scheduled titration.

Weeks 2 to 4, bolus and pattern review

• If on a basal-bolus regimen, ask whether mealtime doses need reassessment; some patients need less mealtime insulin after a switch to a flatter basal profile, but this should be confirmed by glucose patterns, not assumed.
• Reassess for any recurring hypoglycemia pattern (same time of day, same meal) and bring the log to the follow-up visit.

12-week checkpoint

• Recheck A1C and review the full glucose log with the prescriber to confirm the switch achieved its intended goal.

When to seek urgent care rather than wait for a scheduled follow-up

• Recurrent hypoglycemia requiring assistance from another person, or loss of consciousness.
• Signs of diabetic ketoacidosis (persistent vomiting, fruity breath odor, rapid breathing, confusion) in anyone with type 1 diabetes or insulin-dependent type 2 diabetes.
• Glucose readings far outside the expected range that do not respond to the usual correction approach discussed with the care team.

Switching from Tresiba to another basal insulin

Because degludec's action tail persists for an extended period after the last dose, starting a new basal insulin at the next scheduled time will produce a period of overlapping basal coverage. Practical points generally described for reverse switches:

• To glargine U-100: a 1:1 conversion is the usual starting point, with attention to possible mild hypoglycemia risk during the first day or two of overlap.
• To glargine U-300: a 1:1 starting conversion is common, with the possibility of an upward dose adjustment over the following weeks based on the same higher-dose pattern seen with U-300 more generally.
• To detemir (twice daily): detemir is typically divided across two daily injections, and total daily dose often needs to increase compared with the degludec dose, reflecting detemir's different potency per unit. Exact percentage adjustments should come from the prescriber, not a fixed rule.

A cohort analysis addressing reasons patients switch away from degludec has been described in the literature as citing formulary or cost reasons more often than efficacy concerns, with a reported rise in A1C after switching to NPH specifically. This is an observational, non-randomized finding and should be treated as hypothesis-generating rather than a guarantee of what will happen for an individual patient; the specific study should be verified before being cited as a precise statistic.

Tresiba U-100 versus U-200: is a dose conversion needed?

No dose conversion is needed between the U-100 and U-200 FlexTouch pens. The pen's dial delivers the same number of insulin units regardless of concentration; U-200 simply delivers that dose in half the injection volume. This is described in the FDA-approved prescribing information. The U-200 pen allows single injections up to double the maximum volume of the U-100 pen, which is relevant for patients on higher total daily doses who would otherwise need to split an injection.

Should mealtime insulin change during the switch?

For patients on basal-bolus therapy, mealtime insulin doses are typically kept unchanged at the time of the basal switch. Because degludec provides steadier 24-hour coverage with less peak-trough variation than some other basal insulins, some patients later need less mealtime insulin, particularly at breakfast, once dawn-phenomenon-related glucose swings are dampened. Clinical trial data in type 1 diabetes populations have described a modest mealtime dose reduction accompanying a switch to degludec over roughly a year of follow-up; the exact magnitude reported in any single trial should be confirmed against the source rather than treated as universally applicable.

Special populations: kidney disease and older adults

Degludec's pharmacokinetics are not thought to be substantially altered by moderate renal impairment, but reduced insulin clearance in advanced chronic kidney disease applies to all exogenous insulins, not just degludec. A commonly described conservative approach for patients with significantly reduced kidney function is to apply the standard conversion ratio with an additional dose reduction and to space titration further apart than the usual 3-to-4-day interval, though the exact interval should be set by the treating clinician based on the individual's renal status and hypoglycemia risk.

For older adults, hypoglycemia avoidance is often prioritized more heavily in insulin selection, and reported subgroup data from cardiovascular outcome trials have suggested the hypoglycemia advantage of degludec over glargine is preserved in patients over 65. This is a plausible and clinically relevant signal, but subgroup analyses carry more uncertainty than a trial's primary endpoint and should be discussed as one factor among several, not a stand-alone reason to switch.

Flexible dosing: what the label actually allows

Degludec's label permits some flexibility in dose timing, with a minimum spacing between injections rather than a fixed clock time each day. This flexibility has been studied specifically in trials designed around variable dosing intervals in type 1 diabetes, generally showing comparable glycemic control to fixed-time dosing. This is a genuine differentiator from insulins that require strict same-time dosing, and it can make switching logistically easier for patients whose prior regimen was time-locked. The exact minimum spacing interval and any missed-dose guidance should be taken from the current FDA label rather than assumed, since label language can be updated.

What is established, what is plausible, and what is not established

Established: Degludec has a long half-life and a multi-day accumulation profile that make the first 3 to 4 days after a switch or dose change unsuitable for titration. A 1:1 conversion from once-daily glargine U-100 to degludec is the standard label-supported starting approach. U-100 and U-200 pens deliver equivalent unit doses without conversion.

Plausible but requiring individualized confirmation: The specific percentage dose reductions recommended for twice-daily-to-once-daily consolidation, for glargine U-300 conversions, and for advanced kidney disease are described in clinical guidance and trial literature, but exact figures vary by source and should be confirmed with the prescribing information and the patient's specific clinical picture rather than applied as a fixed rule.

Not established from the material available here: Precise comparative effect sizes (exact hazard ratios, percentage reductions in hypoglycemia, or mealtime dose reduction figures) attributed to specific named trials could not be independently verified against a confirmed source in this review and should not be repeated as precise statistics until checked against the original publication.